Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA H1047R |
| Therapy | Copanlisib + WEHI-539 |
| Indication/Tumor Type | colorectal cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047R | colorectal cancer | no benefit | Copanlisib + WEHI-539 | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of WEHI-539 to Aliqopa (copanlisib) did not result in greater inhibition of growth in murine-derived colorectal cancer organoids harboring PIK3CA H1047R in culture (PMID: 40635161). | 40635161 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40635161) | BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer. | Full reference... |